In a quarterly filing that reflects its portfolio as of June 30, 2026, prominent life sciences investor Baker Bros. Advisors disclosed it had completely sold its stake in Abivax S.A. The position consisted of 875,800 shares, valued at approximately $97.52 million at the end of the first quarter.
This disclosure, made public on August 14, reflects trading activity that occurred sometime between April and June. The exit precedes several key recent events for Abivax, including the closing of a $920 million public offering in early July and a positive pre-NDA interaction with the FDA for its lead drug candidate, obefazimod, announced at the end of July. In June, the company had released positive late-stage maintenance data for the drug in ulcerative colitis.